The European Commission has granted marketing authorization to Pfizer for Abrysvo, its respiratory syncytial virus (RSV) vaccine, for use in adults aged 60 years and older. This approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Abrysvo is designed to help protect older adults from lower respiratory tract disease caused by RSV, a common and potentially serious respiratory infection. The decision is based on data from a large-scale clinical trial demonstrating the vaccine's efficacy and safety in the target population.

This authorization enables the vaccine to be marketed across the European Union, providing a new preventive option for healthcare professionals managing RSV risk in older adults. For more information, visit the official announcement on the Pfizer website.